SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma;...

ver descrição completa

Detalhes bibliográficos
Autores: Pérez Segura, Pedro, Vilariño Quintela, Noelia, Martínez García, María, Barco Berrón, Sonia del, Gironés i Sarrió, Regina, García Gómez, Jesús, García Castaño, Almudena, Navarro Martín, Luis Miguel, Gallego Rubio, Óscar, Pineda Losada, Estela
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/59966
Acesso em linha:http://hdl.handle.net/10230/59966
http://dx.doi.org/10.1007/s12094-023-03245-y
Access Level:acceso abierto
Palavra-chave:Epidemiology
High-grade gliomas
Management
Molecular
Treatment
id ES_97e32daf2b11c4e7b38567f9eef95c3f
oai_identifier_str oai:repositori.upf.edu:10230/59966
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)Pérez Segura, PedroVilariño Quintela, NoeliaMartínez García, MaríaBarco Berrón, Sonia delGironés i Sarrió, ReginaGarcía Gómez, JesúsGarcía Castaño, AlmudenaNavarro Martín, Luis MiguelGallego Rubio, ÓscarPineda Losada, EstelaEpidemiologyHigh-grade gliomasManagementMolecularTreatmentHigh-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.Springer202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/59966http://dx.doi.org/10.1007/s12094-023-03245-yreponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésClin Transl Oncol. 2023 Sep;25(9):2634-46© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/599662026-06-12T07:21:37Z
dc.title.none.fl_str_mv SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
title SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
spellingShingle SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Pérez Segura, Pedro
Epidemiology
High-grade gliomas
Management
Molecular
Treatment
title_short SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
title_full SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
title_fullStr SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
title_full_unstemmed SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
title_sort SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
dc.creator.none.fl_str_mv Pérez Segura, Pedro
Vilariño Quintela, Noelia
Martínez García, María
Barco Berrón, Sonia del
Gironés i Sarrió, Regina
García Gómez, Jesús
García Castaño, Almudena
Navarro Martín, Luis Miguel
Gallego Rubio, Óscar
Pineda Losada, Estela
author Pérez Segura, Pedro
author_facet Pérez Segura, Pedro
Vilariño Quintela, Noelia
Martínez García, María
Barco Berrón, Sonia del
Gironés i Sarrió, Regina
García Gómez, Jesús
García Castaño, Almudena
Navarro Martín, Luis Miguel
Gallego Rubio, Óscar
Pineda Losada, Estela
author_role author
author2 Vilariño Quintela, Noelia
Martínez García, María
Barco Berrón, Sonia del
Gironés i Sarrió, Regina
García Gómez, Jesús
García Castaño, Almudena
Navarro Martín, Luis Miguel
Gallego Rubio, Óscar
Pineda Losada, Estela
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Epidemiology
High-grade gliomas
Management
Molecular
Treatment
topic Epidemiology
High-grade gliomas
Management
Molecular
Treatment
description High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/59966
http://dx.doi.org/10.1007/s12094-023-03245-y
url http://hdl.handle.net/10230/59966
http://dx.doi.org/10.1007/s12094-023-03245-y
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clin Transl Oncol. 2023 Sep;25(9):2634-46
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414116400037888
score 15.812429

Registos relacionados